Osimertinib: prices and alternatives
Osimertinib is a third-generation EGFR kinase inhibitor indicated as adjuvant therapy following tumor resection in adults with NSCLC harboring EGFR exon 19 deletions or exon 21 L858R mutations, for locally advanced unresectable stage III NSCLC after chemoradiation, and for metastatic EGFR-mutant NSCLC including…
2 products with this active ingredient from 1 manufacturer. Official price: 124000 EGP.
Every box with this active ingredient, cheapest first.
Informational only — may be inaccurate or incomplete. Don't rely on it medically; verify with a pharmacist.

